Enrolment completed for phase 3 of Horizon’s Tyroid eye disease trial
Horizon Pharma has stated that their Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) has completed enrolment ahead of schedule. TED is a rare autoimmune disease where the insulin-like growth factor receptor (IGF-1R) is overexpressed on eye tissues, which then leads to local inflammation, orbital fibroblast proliferation and